Integrating Novel Approaches in Psoriasis Management: Closing the Gaps with Innovative Treatment Strategies

 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2023 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2024 to March 1, 2025
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Arcutis Biotherapeutics and Bristol Myers Squibb

Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million of the population in the United States. Psoriasis is a periodic flare-up of sharply defined red patches, covered by a silvery, flaky surface. The main disease activity leading to psoriasis occurs in the epidermis, the top five layers of the skin. The disease most commonly appears on the skin of the scalp, elbow, knees, and lumbosacral areas of the body. Many of the patients are not receiving the appropriate treatment discussed in the current guidelines and standards of care. Psoriasis is a complex disease to manage, but the goal should be a patient-centered treatment that reduces disease burden, improves quality-of-life, and addresses the risks of systemic complications and comorbid conditions. The under diagnosis and treatment of psoriasis continues to be a serious concern. It is for these reasons that there needs to be continuing education that addresses the treatment gaps and challenges in the diagnosis, treatment, and management of psoriasis.

Upon completion of this activity, participants will be able to:

  • Apply updated clinical data and guidelines for appropriate tools to the diagnosis and assessment of psoriasis patients to guide treatment decisions

  • Differentiate efficacy and safety profiles of current and emerging therapies for psoriasis to make informed therapy selection for patients

  • Utilize best practices that close the gaps and meet the needs in psoriasis care, including patient-centered factors, personalized care, and navigation of disease severity and complexities

  • Identify the latest clinical data on novel and recently approved targeted treatment approaches for psoriasis

  • Evaluate innovative strategies for shared decision-making engagement with psoriasis patients, including managed care considerations to optimize treatment outcomes, quality of life, and manage costs
     

Faculty: April W. Armstrong, MD, MPH
Professor and Chief
Division of Dermatology
University of California Los Angeles

As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosure:

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Armstrong has served as a consultant for Almirall, Arcutis, ASLAN, Beiersdorf, BMS, Dermavant, Lilly, Galderma, Incyte, Janssen, LEO, Modernizing Medicine, Nimbus, Novartis, Ortho Derm, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. She has received grant/research support from Abbvie, ASLAN, BMS, Dermavant, Lilly, Galderma, Incyte, Janssen, LEO, Nimbus, Novartis, Ortho Derm, Pfizer, Sanofi, and UCB. She has served as a speaker for Abbvie, BMS, Regeneron, Sanofi, and UCB. All relevant conflicts of interest have been mitigated.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Arcutis Biotherapeutics and Bristol Myers Squibb


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue